Additional Treatments Offer Little Benefit for Pancreatic Cancer: Study
TUESDAY, May 3, 2016 -- Additional treatments for locally advanced pancreatic cancer don't appear to boost survival, a new French study reports.
Researchers looked at the effects of adding a second drug -- erlotinib (Tarceva) -- to the initial...
Source: Drugs.com - Daily MedNews - Category: Journals (General) Source Type: news
More News: Cancer | Cancer & Oncology | General Medicine | Pancreas | Pancreatic Cancer | Study | Tarceva